Skip to content

Development and Clinical Translational Application of Anti-Tuberculosis Drug TDM Detection System Based on Dry Blood Spot-HPLC-MS/MS Technology

Development and Clinical Translational Application of Anti-Tuberculosis Drug TDM Detection System Based on Dry Blood Spot-HPLC-MS/MS Technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116000
Enrollment
Unknown
Registered
2026-01-04
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

DBS Detection Technology Verification Group:None

Sponsors

Hangzhou Red Cross Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Confirmed tuberculosis patients (including general tuberculosis and multi-drug resistant tuberculosis); 2.Age 18-75 years; 3.Is currently undergoing anti-tuberculosis medication treatment; 4.Voluntarily sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Patients with severe coagulation dysfunction; 2.Patients with end-stage liver and kidney failure; 3.Individuals with mental illnesses who are unable to cooperate;

Design outcomes

Primary

MeasureTime frame
Consistency between DBS and venous blood anti-tuberculosis drug concentration detection results;

Secondary

MeasureTime frame
Clinical efficacy indicators for tuberculosis patients (sputum conversion rate, lesion absorption);Incidence rate of adverse events related to DBS sampling;Incidence of adverse reactions related to anti-tuberculosis drug treatment;

Countries

China

Contacts

Public ContactChongyang Wu

Hangzhou Red Cross Hospital

wuchongyang0912@qq.com+86 571 5610 9608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026